TerminatedNot Applicable

Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

Stopped: Closure of Drexel University Hahnemann Hospital where Referring Physician Worked

United States7 participantsStarted 2015-08-10

Plain-language summary

The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Individuals receiving anti-epileptic drugs as a treatment for epilepsy Exclusion Criteria: * Individuals who are pregnant or breastfeeding, receiving cancer treatments, have liver or kidney diseases, autoimmune diseases, or other diseases that may interfere with vitamin D and magnesium metabolism.

What they're measuring

Bone mineral density

Timeframe: 1 time point - baseline

Trial details

NCT IDNCT03471481

SponsorDrexel University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-08-01

View on ClinicalTrials.gov More Epilepsy trials